
    
      This is a multi-center, randomized, double-blind, placebo-controlled study.

      Patients who meet the entry IPSS inclusion criteria at Week 0 will be randomized and enroll
      in the double-blind treatment period. Patients will be randomized to one of three treatment
      arms and will receive two 6-month courses of study drug administered on Days 0 and 14 of each
      6-month course. Treatment arms include: ozarelix 30mg + 15mg, ozarelix 15mg + 15mg or placebo
      + placebo. Safety and efficacy assessments will be performed at defined intervals throughout
      the study. At Week 52 all patients on study will be eligible to receive ozarelix for two
      additional courses in the open-label treatment period.
    
  